Advances in nanotechnology-based platforms for survivin-targeted drug discovery

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Survivin, an inhibitor of apoptosis protein (IAP), is a key target in cancer due to its role in proliferation, apoptosis, DNA repair, and immune response.
• Previous survivin-targeting therapeutics faced clinical limitations, necessitating advanced delivery systems.
• Nanotechnology offers potential solutions for precise and controlled delivery of survivin therapeutics.

Purpose of the Study:

• To review advancements in nanocarriers for targeting survivin in human malignancies.
• To explore various nanoparticle platforms and their application in survivin-tailored therapies.
• To highlight the potential of nanomedicine in developing personalized cancer treatments.

Main Methods:

• Review of nanoparticle platforms including liposomes, polymeric systems, dendrimers, inorganic nanocarriers, RNA/DNA nanotechnology, and exosomes.
• Discussion of survivin-tailored strategies such as RNA interference, small molecule inhibitors, dominant negative mutants, and vaccination.
• Exploration of combination therapies involving nanocarriers with chemotherapy and photodynamic/photothermal strategies.

Main Results:

• Nanocarriers enable precise and controlled delivery of gene silencing or drug molecules to target survivin.
• Surface modification of nanocarriers can achieve tumor entity-specific delivery.
• Multimodal nanomedicine strategies exploiting survivin targeting show promise for enhancing therapeutic outcomes.

Conclusions:

• Nanomedicine offers a promising approach to overcome limitations of conventional survivin-targeting therapeutics.
• Advanced nanocarrier systems facilitate targeted delivery and enhanced efficacy of survivin-tailored treatments.
• Exploiting nanomedicine for survivin targeting in a multimodal context is crucial for advancing personalized cancer medicine.